NasdaqGM - Delayed Quote USD

Kymera Therapeutics, Inc. (KYMR)

Compare
42.13 -0.04 (-0.09%)
At close: December 13 at 4:00:02 PM EST
42.13 0.00 (0.00%)
After hours: December 13 at 4:20:00 PM EST

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. Bruce L. Booth DPHIL, Ph.D. Co-Founder & Independent Chairman 75k -- 1974
Dr. Nello Mainolfi M.D., Ph.D. Co-Founder, President, CEO & Director 1.08M 457.97k 1979
Mr. Bruce N. Jacobs CFA Chief Financial Officer 671.2k 249.77k --
Dr. Jeremy G. Chadwick Ph.D. Chief Operating Officer 614.5k -- 1963
Ms. Ellen V. Chiniara Esq., J.D. Chief Legal Officer & Corporate Secretary 640.35k -- 1959
Dr. Jared A. Gollob M.D. Chief Medical Officer 723.6k -- 1965
Ms. Karen Weisbach Head of People & Culture -- -- --
Dr. Juliet Williams B.A Ph.D. Head of Research -- -- --

Kymera Therapeutics, Inc.

200 Arsenal Yards Boulevard
Suite 230
Watertown, MA 02472
United States
857 285 5300 https://www.kymeratx.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
184

Description

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Corporate Governance

Kymera Therapeutics, Inc.’s ISS Governance QualityScore as of December 1, 2024 is 7. The pillar scores are Audit: 3; Board: 8; Shareholder Rights: 8; Compensation: 8.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

February 20, 2025 at 1:30 PM UTC - February 24, 2025 at 1:30 PM UTC

Kymera Therapeutics, Inc. Earnings Date

Recent Events

December 4, 2024 at 9:15 PM UTC

at Evercore ISI HealthCONx Conference

December 3, 2024 at 6:00 PM UTC

at Piper Sandler Healthcare Conference

November 20, 2024 at 4:00 PM UTC

at Jefferies London Healthcare Conference

November 19, 2024 at 2:20 PM UTC

at Wolfe Research Healthcare Conference

November 18, 2024 at 4:30 PM UTC

at Stifel Healthcare Conference

November 14, 2024 at 12:00 AM UTC

SC 13G/A: Tender Offer/Acquisition Reports

November 12, 2024 at 3:00 PM UTC

at Guggenheim Global Healthcare Conference

October 31, 2024 at 12:30 PM UTC

Q3 2024 Earnings Call

October 31, 2024 at 12:00 AM UTC

S-3ASR: Offering Registrations

September 17, 2024 at 3:30 PM UTC

at Cantor Global Healthcare Conference

Related Tickers